Organization | Tai'an Central Hospital

Tai'an Central Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Tai'an China (1993)

Organization Overview

First Clinical Trial

2014

NCT02412319

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Taian Central Hospital | Taian City Central Hospital | Tai'an People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (15)

allogeneic cord blood (2 trials)

amoxicillin (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bismuth (1 trial)

Bismuth Subcitrate Potassium (Pylera) (1 trial)

clarithromycin (biaxin) (1 trial)

clostridium butyricum (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

entecavir (baraclude) (1 trial)

metronidazole (flagyl) (1 trial)

polyethylene glycol (1 trial)

prucalopride (1 trial)

tetracycline (tetrex) (1 trial)

vonoprazan (Voquezna) (1 trial)

Drugs in Phase 3 Trials (3)

borneol (1 trial)

cytarabine (cytosar-u) (1 trial)

decitabine (dacogen) (1 trial)

Drugs in Other Trials (2)

azacitidine (vidaza) (1 trial)

omacetaxine (synribo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 4)

Anemia, Aplastic (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 20